![Emil Kakkis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Emil Kakkis
Gründer bei
ULTRAGENYX PHARMACEUTICAL INC.
Vermögen: 90 Mio $ am 30.06.2026
Profil
Emil D. Kakkis gründete Ultragenyx Pharmaceutical, Inc. und die Everylife Foundation for Rare Diseases. Dr. Kakkis bekleidet die Position des President, Chief Executive Officer & Director bei Ultragenyx Pharmaceutical, Inc. Dr. Kakkis ist außerdem im Vorstand des Emil Kakkis & Jenny Soriano Living Trust und von Odylia Therapeutics sowie Präsident der Everylife Foundation for Rare Diseases. In seiner früheren Karriere war Dr. Kakkis Chief Medical Officer & Senior Vice President bei BioMarin Pharmaceutical, Inc. und Assistenzprofessor am Harbor-UCLA Medical Center. Dr. Kakkis erwarb einen Bachelor-Abschluss am Pomona College und einen Doktortitel an der David Geffen School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.04.2026 | 2’694’724 ( 2.74% ) | 90 Mio $ | 30.06.2026 |
Aktuelle Nachrichten zu Emil Kakkis
Aktive Positionen von Emil Kakkis
| Unternehmen | Position | Beginn |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Gründer | 22.04.2010 |
Emil Kakkis & Jenny Soriano Living Trust | Direktor/Vorstandsmitglied | - |
Everylife Foundation for Rare Diseases
 Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization, which dedicates to accelerating rare disease treatments | Gründer | 01.03.2009 |
Odylia Therapeutics
 Odylia Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit biotech that develops therapies for rare diseases | Direktor/Vorstandsmitglied | 01.01.2019 |
Ehemalige bekannte Positionen von Emil Kakkis
| Unternehmen | Position | Ende |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.02.2009 |
Harbor-UCLA Medical Center
 Harbor-UCLA Medical Center Medical/Nursing ServicesHealth Services Provides medical practice, education and research services | Corporate Officer/Principal | 01.01.1998 |
Ausbildung von Emil Kakkis
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
67
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Pomona College
 Pomona College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
David Geffen School of Medicine
 David Geffen School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harbor-UCLA Medical Center
Harbor-UCLA Medical Center Medical/Nursing ServicesHealth Services Provides medical practice, education and research services | Health Services |
Emil Kakkis & Jenny Soriano Living Trust | |
Everylife Foundation for Rare Diseases
Everylife Foundation for Rare Diseases Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization, which dedicates to accelerating rare disease treatments | Commercial Services |
Odylia Therapeutics
Odylia Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit biotech that develops therapies for rare diseases | Commercial Services |
Wählen Sie MarketScreener 
